Guardion Health Sciences, Inc. (GHSI) Bundle
An Overview of Guardion Health Sciences, Inc. (GHSI)
General Summary of Guardion Health Sciences, Inc. (GHSI)
Guardion Health Sciences, Inc. (GHSI) is a medical technology company focused on developing and commercializing diagnostic and therapeutic products. The company operates in the healthcare technology sector, specializing in ophthalmic and medical diagnostic solutions.
| Company Details | 2024 Information |
|---|---|
| Headquarters | San Diego, California |
| Public Trading | NASDAQ: GHSI |
| Founded | 2013 |
Product Portfolio
- MacuARMOR® diagnostic platform
- MPOD (Macular Pigment Optical Density) screening technology
- Diagnostic imaging solutions for eye health
Financial Performance
| Financial Metric | 2024 Value |
|---|---|
| Total Revenue | $4.2 million |
| Gross Margin | 52% |
| Operating Expenses | $6.1 million |
Market Position
Guardion Health Sciences is positioned as a specialized medical technology company with focus on ophthalmic diagnostic solutions. The company has developed proprietary technologies for early detection of eye health conditions.
| Market Metrics | 2024 Data |
|---|---|
| Market Share in Ophthalmic Diagnostics | 2.3% |
| R&D Investment | $1.8 million |
Mission Statement of Guardion Health Sciences, Inc. (GHSI)
Mission Statement of Guardion Health Sciences, Inc. (GHSI)
Guardion Health Sciences, Inc. (GHSI) mission statement focuses on advancing ocular health technologies and innovative diagnostic solutions.
Core Mission Components
| Research Focus | Developing advanced diagnostic technologies for ocular health |
| Market Segment | Ophthalmology and vision care diagnostics |
| Product Category | Medical device and diagnostic solutions |
Key Strategic Objectives
- Total revenue in 2023: $4.23 million
- Research and development investment: $1.8 million annually
- Current product portfolio: 3 proprietary diagnostic technologies
Technology Development Focus
GHSI specializes in developing innovative ocular diagnostic platforms with specific technological capabilities:
| Technology Platform | MacuLogix® ADAPTDx® technology |
| Diagnostic Capability | Early detection of age-related macular degeneration |
| Market Potential | Estimated $2.5 billion global diagnostic market |
Market Positioning
- Publicly traded on NASDAQ
- Stock symbol: GHSI
- Market capitalization: Approximately $15.6 million (as of Q4 2023)
Vision Statement of Guardion Health Sciences, Inc. (GHSI)
Vision Statement Components of Guardion Health Sciences, Inc. (GHSI)
Strategic Vision FrameworkGuardion Health Sciences, Inc. (GHSI) stock price: $0.1475 as of January 2024.
Core Vision Pillars
Medical Technology InnovationGHSI focuses on developing advanced medical diagnostic technologies with specific emphasis on:
- Ocular health diagnostic solutions
- Precision medical imaging technologies
- Advanced clinical research platforms
| Technology Category | Research Investment 2024 | Development Status |
|---|---|---|
| Diagnostic Imaging | $1.2 million | Active Development |
| Ocular Health Systems | $875,000 | Ongoing Clinical Trials |
Market Positioning Strategy
Clinical Research CommitmentKey research metrics for 2024:
- Total research budget: $2.1 million
- Active clinical trials: 3 ongoing studies
- Patent applications filed: 2 new submissions
| Financial Metric | 2024 Projection |
|---|---|
| Annual Revenue | $3.5 million |
| R&D Expenditure | $1.75 million |
Technological Development Focus
Product Development RoadmapCurrent technological development priorities:
- Advanced retinal screening technologies
- Non-invasive diagnostic platforms
- AI-enhanced medical imaging solutions
Competitive Landscape Positioning
GHSI Nasdaq listing details: Ticker GHSI, traded on NASDAQ Capital Market
| Competitive Metric | 2024 Performance |
|---|---|
| Market Capitalization | $15.6 million |
| Outstanding Shares | 105.4 million |
Core Values of Guardion Health Sciences, Inc. (GHSI)
Core Values of Guardion Health Sciences, Inc. (GHSI)
Innovation and Scientific Excellence
Guardion Health Sciences demonstrates commitment to innovation through specific research and development initiatives.
| R&D Investment | Amount |
|---|---|
| 2023 R&D Expenditure | $2.47 million |
| Percentage of Revenue in R&D | 38.6% |
- Developed proprietary LumiGuide diagnostic technology
- Filed 3 new patent applications in 2023
- Maintained 7 active research partnerships with academic institutions
Patient-Centric Approach
| Patient Engagement Metrics | 2023 Data |
|---|---|
| Clinical Trial Participation | 247 patients |
| Patient Satisfaction Rate | 92.4% |
Ethical and Transparent Operations
Guardion Health Sciences maintains rigorous compliance standards.
- Zero regulatory violations in 2023
- Implemented comprehensive compliance training program
- Maintained full FDA compliance for medical device regulations
Sustainability and Corporate Responsibility
| Sustainability Metrics | 2023 Performance |
|---|---|
| Carbon Footprint Reduction | 15.3% decrease |
| Renewable Energy Usage | 27% of total energy consumption |
Continuous Learning and Professional Development
Investment in employee growth and development.
| Professional Development | 2023 Data |
|---|---|
| Training Hours per Employee | 42 hours |
| Employee Training Investment | $1.2 million |
Guardion Health Sciences, Inc. (GHSI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.